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Direct (intracisternal) injection of aluminum complexes into rabbit brain results in a number of
similarities with the neuropathological and biochemical changes observed in Alzheimer’s disease and
provides the opportunity to assess early events in neurodegeneration. This mode of administration
induces cytochrome c release from mitochondria, a decrease in Bcl-2 in both mitochondria and
endoplasmic reticulum, Bax translocation into mitochondria, activation of caspase-3, and DNA fragmentation. Coadministration of glial cell neuronal-derived factor (GDNF) inhibits these Bcl-2 and Bax
changes, upregulates Bcl-X L, and abolishes the caspase-3 activity. Furthermore, treatment with GDNF
dramatically inhibits apoptosis, as assessed by the TUNEL technique for detecting DNA damage.
Treatment with GDNF may represent a therapeutic strategy to reverse the neuronal death associated
with Alzheimer’s disease and may exert its effect on apoptosis-regulatory proteins. © 2001 Academic Press
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INTRODUCTION

Alzheimer’s disease is a progressive neurodegenerative disorder characterized by three typical pathological features, namely the extracellular deposition of
A␤, the formation of neurofibrillary tangles, and selective neuronal loss. However, it is unclear which of
these pathological features is the primary event in the
initiation and progression of this disease. Selective
neuronal death involves vulnerable brain regions, in
particular the hippocampus and cerebral cortex, and
apoptosis may play a role in the process of cell loss
(for review, see Honig & Rosenberg, 2000). Besides
inducing intraneuronal neurofilamentous changes in
the cerebral, cortex, brainstem, and spinal cord, which
demonstrate many biochemical features in common
with the neurofibrillary tangles seen in Alzheimer’s
disease (Rao et al., 2000; Huang et al., 1997), the intracisternal administration of Al maltolate to rabbits also
leads to biochemical changes suggestive of apoptosis
(Savory et al., 1999). Aluminum is highly neurotoxic

An understanding of the complex events involved in
neuronal injury and protection in neurodegenerative
diseases requires the availability of animal model systems. The direct injection of aluminum (Al) compounds
into the brain of rabbits has been found to result in
conditions that mimic a number of neuropathological
and biochemical changes present in Alzheimer’s and
related human neurodegenerative disorders (Huang et
al., 1997). The use of this animal model should not be
confused with the ongoing controversy regarding the
possible role of Al in the pathogenesis of Alzheimer’s
disease, a debate which by no means has been concluded
(Savory et al., 1996). Here we use this Al/rabbit model
system to unravel the events leading to neuronal apoptosis and, most importantly, to demonstrate the antiapoptotic effect of glial cell line-derived neurotrophic
factor (GDNF) against fatal Al neurotoxicity.
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and has been shown to accumulate in neurons following cell depolarization (Suarez Fernandez et al., 1996),
where it inhibits Na ⫹/Ca ⫹2 exchange and thereby induces an excessive accumulation of mitochondrial
Ca ⫹2 (Szutowicz et al., 1998). Increases in intramitochondrial Ca ⫹2 levels lead to an opening of the mitochondrial transition pore (MTP), with cytochrome c
release and subsequent apoptosis resulting from activation of the caspase family of proteases. This mitochondrial pathway is now widely considered to be an
important step in controlling and initiating apoptosis
in neurodegenerative disorders and involves regulating proteins such as the anti-apoptotic Bcl-2 and BclX L, and the proapoptotic Bax. The present study was
initiated to assess the importance of such apoptosis
regulation, especially to see whether agents that upregulate Bcl-2 and Bcl-X L will be protective in the
Al/rabbit system. Recently, it has been reported that
GDNF provides an antiapoptotic effect on primary
cultures of the rat mesencephalon (Sawada et al.,
2000), causing an increase in Bcl-2 and Bcl-X L. Here we
demonstrate that GDNF has indeed a markedly antiapoptotic effect in our system, and we have examined
factors such as mitochondrial cytochrome c release,
changes in Bcl-2 in mitochondria and endoplasmic
reticulum, Bcl-X L regulation, Bax translocation into
mitochondria, caspase-3 activation, and DNA fragmentation.

MATERIALS AND METHODS
Animals, Treatment Protocol, Clinical Monitoring,
and Tissue Collection
All animal procedures were carried out in accordance
with the U.S. Public Health Service Policy on the Humane Care and Use of Laboratory Animals, and the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals. The animal protocol was approved by the University of Virginia Animal Care and
Use Committee. Young adult (5– 8 months) female New
Zealand white rabbits received either intracisternal injections of 100 l normal saline (n ⫽ 6; controls), 100 l 50
mM Al maltolate in saline (n ⫽ 7; Al-treated group), or
100 l of 500 ng/ml GDNF in saline plus 100 l 50 mM
Al maltolate (n ⫽ 6; Al/GDNF-treated group). The
GDNF was obtained commercially (R&D systems, Inc.,
Minneapolis, MN). The injections were carried out
slowly over a period of 2 min under ketamine anesthesia
as described previously (Savory et al., 1999). All rabbits
were monitored daily for clinical symptoms as described

by us previously (Huang et al., 1997). Rabbits were euthanized 3 days following the intracisternal injection and
perfused with Dulbecco’s phosphate buffered saline
(GIBCO, Grand Island, NY), also as described previously
(Savory et al., 1999). Brains were immediately removed
after sacrifice, and a coronal section cut and bisected to
yield two symmetrical hippocampal segments, one for
immunohistochemistry and the other for immunoblot
analysis and caspase-3-like activity measurements. The
respective sides chosen for these studies were alternated
between successive animals. Each brain hemisphere intended for tissue sectioning was immediately frozen rapidly on a liquid nitrogen-cooled surface, placed into a
zipper-closure plastic bag, and buried in dry ice pellets
until transferring to ⫺80°C before sectioning. For immunoblot and caspase-3-like activity analysis, the hippocampus was rapidly dissected, homogenized, and
processed as described below.
Western Blot Analysis
We examined changes of proteins in the subcellular
fractions where they are reported to be localized
and/or translocated. Bcl-2 is present in mitochondria
and the endoplasmic reticulum and does not translocate into the cytoplasm, unlike cytochrome c, which
does; Bax also translocates, but from the cytoplasm to
mitochondria (Cassarino et al., 1999; Cory, 1995; Eskes
et al., 1998). For Bcl-X L we assessed levels in both the
mitochondrial and cytoplasmic fractions.
Proteins from the mitochondrial, cytosolic and endoplasmic reticulum fractions were extracted as described previously (Liu et al., 1996). Tissue from the
entire hippocampus was gently homogenized, using a
teflon homogenizer (Thomas, Philadelphia, PA), in 7
vol of cold suspension buffer (20 mM Hepes–KOH
(pH 7.5), 250 mM sucrose, 10 mM KCl, 1.5 mM MgCl 2,
1mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1 mM PMSF,
2 mg/ml aprotinin, 10 mg/ml leupeptin, 5 mg/ml
pepstatin and 12.5 mg/ml of N-acetyl-Leu-Leu-Norleu-Al). The homogenates were centrifuged at 750g at
4°C for 10 min to first isolate the nuclear fraction, and
then at 8000g for 20 min at 4°C to separate the mitochondrial from the soluble fraction. The 8000g pellets
were resuspended in cold buffer without sucrose and
used as the mitochondrial fraction. The supernatant
was further centrifuged at 100,000g for 60 min at 4°C
to separate the cytosolic from the endoplasmic reticulum fractions. Protein concentrations were determined
with the BCA protein assay reagent (Pierce, Rockford,
IL). Proteins (7.5 g) from the mitochondrial, cytosolic, and endoplasmic reticulum fractions were sepaCopyright © 2001 by Academic Press
All rights of reproduction in any form reserved.
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rated by SDS–PAGE (15% gel) under reducing conditions, followed by transfer to a polyvinylidene difluoride membrane (Millipore, Bedford, MD), at 300 mA
for 210 min in transfer buffer (20 mM Tris-base, 150
mM glycine, 20% methanol). Following transfer, membranes were incubated with mouse monoclonal antibody (mAb) to human cytochrome c, Bcl-2 (C-2), Bax
(B-9), or Bcl-X L (H-5), all at a dilution of 1:100. All of
these mAbs were obtained from a commercial source
(Santa Cruz Biotechnology, Santa Cruz, CA). Cytochrome oxidase subunit IV mAb obtained from a commercial source (Molecular Probes, Eugene, OR) was
used as a marker of mitochondrial contamination at
1:1000 dilution, and a calnexin mAb (Transduction
Laboratories, Lexington, MD) was applied at 1:500
dilution as an endoplasmic reticulum marker. Following washes with Tris-buffered saline (TBS) containing
0.1% Triton X-100, the blots were developed with enhanced chemiluminescence (Immun-Star goat antimouse IgG detection kit, Bio-Rad, Hercules, CA). The
bands representing cytochrome c, Bax, Bcl-2, and
Bcl-X L were developed on radiographic film and analyzed by densitometry with Personal Densitometer SI
and Image Quant 5.0 software (Molecular Dynamics,
Sunnyvale, CA).
Caspase-3-like Activity Assay
Lysates were prepared by homogenizing hippocampal tissue in 20 mM Hepes-KOH (pH 7.5), 250 mM
sucrose, 10 mM KCl, 1.5 mM MgCl 2, 1 mM EDTA, 1
mM EGTA, 1 mM DTT, 0.1 mM PMSF. Lysates were
centrifuged at 4°C for 30 min at 160,000g, and the
protein concentration in the supernatant was determined using the Bradford method. Lysates (50 g
protein) were incubated for 1 h at 37°C in 1 ml of 1⫻
Hepes buffer containing 10 L of the fluorogenic substrate Ac-DEVD-AMC, with and without 10 L of the
caspase-3 inhibitor Ac-DEVD-CHO (Caspase-3 assay
kit, Pharmingen, San Diego, CA). Cleavage of the
substrate was monitored at an excitation wavelength
of 380 nm and emission wavelength of 440 nm using a
Model 450 fluorometer (BioMolecular Inc.). Caspase-3
activity for each sample was calculated as the difference between the rate of cleavage in the absence and
presence of the inhibitor.
DNA Fragmentation and Immunohistochemistry
Frozen coronal brain sections (14 m thick) from the
hippocampal level were fixed and permeabilized as
described previously (Henshall et al., 2000). Detection
Copyright © 2001 by Academic Press
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of DNA fragmentation was performed using the terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) technique. In brief, tissue
sections from controls, Al-treated, and Al/GDNFtreated animals were dried for 15 min at room temperature and fixed in 10% formalin for 15 min, followed by 10 min incubation in 1:2 vol/vol ethanol/
acetic acid. Sections were washed three times in PBS
for 5 min each, permeabilised with 3% Triton X-100 for
20 min and immersed in 3% hydrogen peroxide for 15
min. Sections were then washed three times in PBS
buffer for 5 min each and then processed for apoptosis
detection using an Apoptosis Detection System, Fluorescein (Promega, Madison, Wisconsin). Positive control fixed sections were incubated with 1 unit/ml of
Dnase I for 5 min. All steps were conducted at room
temperature.
For dual-labeled caspase-3 immunostaining, brain
sections previously stained with the TUNEL from controls, Al-treated, and Al/GDNF-treated animals were
blocked with 2% goat serum and incubated for 2 h at
37°C in a 1:200 dilution of the caspase-3/CPP 32
mouse mAb, specific for activated caspase-3 (Transduction Laboratories, Lexington, KY). Sections were
then washed three times in PBS for 5 min and incubated for 2 h at 37°C in a 1:500 dilution of the Cy3conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania).
Sections were subsequently washed in PBS buffer,
mounted in Vectashield, coverslipped, and evaluated
and recorded digitally with a fluorescence microscope.
TUNEL and caspase-3 positive neurons were counted
at a magnification of 400X with an Olympus BH2
microscope (Melville, NY) and Image Pro Plus 4.1
analysis software (Media Cybernetics, Baltimore,
MD). Five fields were captured from the CA 1 region
of the hippocampus from each animal, and results
were compared between the Al-treated and the Al/
GDNF-treated animals. Results from the Al-treated
rabbits were assigned a value of 100%. The GDNF
effect was then expressed as the percent reduction in
the number of positive neurons in the Al/GDNF
group when compared to the Al-treated rabbits.
Statistical Analysis
Densitometric analysis for cytochrome c, Bcl-2, Bax
and Bcl-X L were expressed as mean ⫾ SE values.
Differences in densitometric levels of these proteins in
mitochondrial, cytoplasmic, and endoplasmic fraction
were statistically compared between the controls, Altreated, or Al/GDNF-treated animals, using ANOVA
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with the posthoc Fisher’s PLSD test. Changes in
caspase-3 protease activity in the different animal
groups were compared using one-way ANOVA and
the Student’s t test. A value ⬍0.05 was considered
significant.

RESULTS
By day 3 following Al maltolate administration, all
animals with this treatment alone develop neurological symptoms characterized by forward head tilt,
hemiplegic gait, loss of appetite, splaying of the extremities, and paralysis. These symptoms were so severe at this time that the rabbits had to be sacrificed.
Treatment with GDNF protected the animals against
this Al-induced toxicity, and no neurological symptoms were evident up to day 3.

Western Blot Analysis
Cytochrome c immunoreactivity, as shown by Western blot and densitometric analysis of these blots (Fig.
1A), is faintly detectable in the cytosolic fraction in the
control brains and is strongly positive in the mitochondrial fractions. Aluminum treatment induces cytochrome c release into the cytoplasm and GDNF administration fails to inhibit the Al-induced translocation of cytochrome c into the cytoplasm.
Bcl-2 (Fig. 1B) is detectable in controls in the mitochondrial and endoplasmic reticulum fractions. In the
Al-treated group, Bcl-2 reactivity is decreased both in
the mitochondria and in the endoplasmic reticulum,
but treatment with GDNF maintains the Bcl-2 levels.
As shown in Fig. 1B, densitometric analysis of Bcl-2
demonstrates that Al dramatically decreases Bcl-2 levels in both the mitochondrial and endoplasmic reticulum fractions and that this effect is reversed by
GDNF.
Bax (Fig. 1C) is distributed with higher intensity in
the cytosolic than in the mitochondrial fractions of
controls. Following Al treatment, Bax immunoreactivity is markedly increased at the mitochondrial level.
Treatment with GDNF significantly decreases Bax intensity in the mitochondria.
Bcl-X L immunoreactivity (Fig. 1D) in controls is
highly positive in the mitochondrial fraction and is
present to a lesser extent in the cytoplasmic fraction.
Aluminum treatment, while having no significant effect on Bcl-X L in mitochondria, slightly increases the
level in the cytoplasmic fraction. GDNF administra-

tion results in an enhancement of Bcl-X L in both the
mitochondrial and cytoplasmic fractions.
Cytochrome c oxidase subunit IV and calnexin antibodies, used respectively as specific markers for mitochondrial and endoplasmic reticulum proteins, confirm the purity of the subcellular fractionation carried
out in the present experiments. As shown in Fig. 2,
cytochrome c oxidase subunit IV stains only the mitochondrial fraction and calnexin stains only the endoplasmic reticulum fractions.
Caspase-3-like Activity
The activity of caspase 3-like proteases in hippocampal lysates, assessed by measuring the cleavage
of the fluorogenic substrate Ac-DEVD-AMC in the
presence and absence of an inhibitor, demonstrates
significant elevations in the Al-treated animals. This
increase in caspase-3-like activity approaches fivefold
greater levels in the Al-treated animals as compared to
controls. Treatment with GDNF strongly reduces the
caspase-3-like activity (Fig. 3).
DNA Fragmentation and Caspase-3
Immunoreactivity
Sections from control animals treated with DNAse I
(positive control) show widespread TUNEL-positive
staining in the pyramidal layer (CAl) of the hippocampus (Fig. 4A), while in a similar area in the control
untreated group no TUNEL (Fig. 4B) or caspase-3
positive neurons (Fig. 4C) are seen. Aluminum administration induces a large number of TUNEL positive
(Fig. 4D) and caspase-3 stained (Fig. 4E) neurons in the
same region of the hippocampus. There are also
TUNEL and caspase-3-positive neurons in the nearby
temporal cortex but to a lesser extent (data not
shown). Treatment with GDNF dramatically reduces
TUNEL positivity (Fig. 4G), and the caspase-3 staining
(Fig. 4H) in these neurons. No positivity for either
TUNEL or caspase-3 is observed in the temporal cortex (data not shown). Quantitation of TUNEL positive
(Figs. 5A and 5B) and caspase-3 positive (Figs. 5D and
5E) neurons, carried out at a magnification of 400X,
shows that the Al-induced TUNEL staining and
caspase-3 activity increase are markedly reduced by
GDNF treatment (Figs. 5C and 5F, respectively).

DISCUSSION
Hippocampal tissue from Al maltolate-treated rabbits exhibits cytochrome c translocation into the cytoCopyright © 2001 by Academic Press
All rights of reproduction in any form reserved.
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FIG. 1. Representative immunoblot and densitometric analyses for cytochrome c Bcl-2, Bax, and Bcl-X L proteins of mitochondrial (m),
cytoplasmic (c), or endoplasmic fractions (er) from hippocampus in controls (n ⫽ 6), the Al-treated group (n ⫽ 7), and Al/GDNF-treated group
(n ⫽ 6). (A) Cytochrome c (15.5 kDa) is localized in the mitochondria and is barely detectable in the cytoplasm of controls. Aluminum
administration induces translocation of cytochrome c into the cytoplasm, and coperfusion with GDNF does not inhibit the Al-induced
cytochrome c translocation (***P ⬍ 0.01; versus controls). (B) Bcl-2 (27 kDa) in controls is localized in mitochondria and the endoplasmic
reticulum. Following Al administration, Bcl-2 levels decrease both in the mitochondria and in the endoplasmic reticulum. Treatment with
GDNF maintains Bcl-2 levels at the basal levels observed in the controls, both in the mitochondria and endoplasmic reticulum (*P ⬍ 0.05, **P ⬍
0.01 versus controls; ⫹P ⬍ 0.05 versus Al treated). (C) Bax (23 kDa) in controls is present at low levels in mitochondria and highly reactive in
the cytoplasm. Aluminum induces an increase in Bax in the mitochondrial fractions, and treatment with GDNF significantly reduces the
translocation of Bax into mitochondria (**P ⬍ 0.01 versus controls; ⫹P ⬍ 0.05 versus Al treated). Note that Bax immunoblotting results in three
distinct bands: the upper band is approximately 54 kDa and the lower band is 23 kDa. (D) Bcl-X L (31 kDa) immunoreactivity in controls is
highly positive in the mitochondrial fraction and is present to a lesser extent in the cytoplasmic fraction. Aluminum induces a slight decrease
in mitochondrial levels, with a subsequent increase in the cytoplasmic levels. GDNF leads to a large increase in Bcl-X L levels in cytoplasm ⬎
mitochondria (*P ⬍ 0.05, **P ⬍ 0.01 versus controls; ⫹P ⬍ 0.05 versus Al treated).

Copyright © 2001 by Academic Press
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FIG. 2. A representative Western blot analysis for cytochrome c
oxidase subunit IV (Cyt.OX) and calnexin in cytoplasmic (c), mitochondrial (m), or endoplasmic reticulum (er) fractions. Cytochrome
c oxidase subunit IV, used as a marker for mitochondrial contamination, is only present in the mitochondrial fraction, and calnexin,
applied as a marker for the endoplasmic reticulum, stains only the
endoplasmic reticulum fraction.

plasm, accompanied by a decrease in Bcl-2 and an
increase in Bax. Furthermore, changes in the levels of
these proteins are accompanied by evidence of activation of caspase-3 and DNA fragmentation, suggestive
of the initiation of apoptosis. Treatment with GDNF
reverses the increase in levels of the proapoptotic protein Bax, and enhances levels of the antiapoptotic proteins Bcl-2 and Bcl-X L, thus abolishing the caspase-3like activity and dramatically inhibiting apoptosis.
Mitochondrial cytochrome c is considered to play a
pivotal role in the initiation of apoptosis when released into the cytoplasm. On the other hand, members of the Bcl-2 family of proteins are believed to
determine cell life or death by inhibiting (as in the case
of Bcl-2 and Bcl-X L), or promoting (as in the case of
Bax), the release of cytochrome c (for a review see
Graham et al., 2000). Opening of the MTP has been
proposed to lead to cytochrome c release; however, it
may not represent the unique mechanism for this release (for review, see Gottlieb, 2000). Indeed, it has
been suggested that Bax, when translocated into mitochondria following neurotoxic stimuli, can by itself
form a channel, or can interact with the voltage-dependent anion channel (VDAC) to form a larger channel that is permeable to cytochrome c (Shimizu et al.,
2000). In the present work it remains to be determined
whether the release of cytochrome c induced by Al
occurs through opening of the MTP and/or as a result
of the increase in mitochondrial Bax. Since Al perturbs
Ca 2⫹ homeostasis in mitochondria (Szutowicz et al.,
1998), it may then open the MTP and release cytochrome c. We recently have reported such a mechanism in aged rabbit brains where the Al-induced cytochrome c release was supressed by cyclosporin A, a
blocker of the MTP (Ghribi et al., 2001).
Treatment with GDNF greatly reduces Bax translocation into mitochondria and increases the levels of
the antiapoptotic Bcl-2 and Bcl-X L, but does not inhibit
cytochrome c release into the cytoplasm. However, the
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GDNF-treated animals show no caspase-3-like activity
and have a markedly reduced number of apoptotic
cells when compared to animals receiving Al. Also,
these GDNF-treated rabbits do not demonstrate neurological symptoms for up to the first 3 days, whereas
within this time period, those receiving Al alone develop severe symptoms and must be sacrificed. The
mechanism by which GDNF exhibits its protective
effect in the present study is unknown and, based on
present results, it appears that the antiapoptotic effect
is independent of the blockade of cytochrome c release. It also seems unlikely that the observed cytochrome c release originates from a putative Bax channel, since GDNF treatment inhibits mitochondrial Bax
translocation and increases mitochondrial Bcl-2 levels,
a process normally capable of inhibiting cytochrome c
release via a Bax-dependent pathway (for review see
Tsujimoto and Shimizu, 2000). However, it has been
shown recently that during tumor necrosis-related
apoptosis-inducing ligand (TRAIL)-induced apoptosis
in Jurkat cells, Bcl-2 overexpression fails to block mitochondrial dysfunction and does not inhibit cytochrome c release (Kim et al., 2001). It is known that
formation of the cytochrome c-Apaf-1 complex (for a
review see Gottlieb, 2000), rather than the presence per
se of cytochrome c in the cytoplasm, is the determining
factor in the activation of caspases and in the triggering of apoptosis. Indeed, it has been reported that the
antiapoptogenic protein Bcl-X L has the ability, when
overexpressed, to sequester Apaf-1, and thereby to

FIG. 3. Caspase-3-like activity in hippocampal lysates of control
(white bar), Al-treated (black bar) and Al/GDNF-treated animals
(hatched bar). In the controls, the level of caspase-3 activity detected
is low. Aluminum treatment induces a large increase (5-fold) in
caspase-3 activity; GDNF treatment completely abolishes the Alinduced caspase-3 like activity. Data are presented as mean ⫾ SEM
(***P ⬍ 0.001 versus controls; ⫹⫹⫹P ⬍ 0.001 versus Al-treated
group). A value of 70 arbitrary fluorescence units corresponds to
50% inhibition of the initial reading when the caspase-3 inhibitor
Ac-DEVD-CHO is added.
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FIG. 4. Immunofluorescence images of TUNEL labeling and caspase-3 protein in the hippocampal CAl area of control, Al-treated, and
Al/GDNF-treated animals. Magnification scale bar in I represents 50 m. (A) TUNEL-positive labeling (positive control) induced by treatment
of tissue section from a naive rabbit with Dnase I. (B) TUNEL labeling of DNA fragmentation from control brain with no positively-stained
neurons. (C) Caspase-3 immunoreactivity in control. (D) TUNEL labeling demonstrates the emergence of DNA fragmentation following Al
administration (arrows). (E) Distinct caspase-3 immunoreactivity is enhanced in the same neurons as in D, from Al-treated rabbits (arrows).
(F) Image overlay of D and E showing colocalization of positive TUNEL labeling with caspase-3 immunoreactivity. Box in F: higher power
magnification of a neuron double-stained with TUNEL and caspase-3. (G) TUNEL labeling following treatment with GDNF shows a reduced
number of neurons exhibiting DNA fragmentation. (H) Caspase-3 immunoreactivity in the CA 1 sector is greatly reduced in rabbits treated
with GDNF. (I) overlay image of G and H demonstrates a reduced number of positive neurons, in comparison to F; TUNEL labeling and
caspase-3 immunoreactivity are colocalized. Box in I: higher power magnification of a neuron double-stained with TUNEL and caspase-3.

inhibit Apaf-1-dependent caspase-9 activation (Hu et
al., 1998; Pan et al., 1998). Interestingly, the GDNFinduced increase in mitochondrial and cytoplasmic
Copyright © 2001 by Academic Press
All rights of reproduction in any form reserved.

Bcl-X L levels we report here may provide, at least in
part, an explanation for the antiapoptotic effect of
GDNF. By upregulating Bcl-X L levels in the cyto-
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FIG. 5. TUNEL-positive (A and B) and caspase-3 positive (D and E) cells in the CAl region of the hippocampus, with quantitation of the
results, in Al treated and in Al/GDNF treated animals. The Al-induced TUNEL labeling (A) and caspase-3 activation (D) are markedly reduced
by GDNF treatment, (B) and (E), respectively. (C and F) Quantitative analyses showing the neuroprotective effect of GDNF which reduces the
number of TUNEL-positive (C) and caspase-3 positive (F) neurons in comparison to Al-treated animals. (A, B, D, and E, 400⫻).

plasm, this protein can bind to Apaf-1, leaving cytochrome c free but now unable to initiate caspase-9
activation.
Although mitochondrial alterations represent a major step in the initiation of apoptosis, increasing evidence now implicates the endoplasmic reticulum as an
important organelle in the regulation of apoptosis. The
endoplasmic reticulum-mediated apoptosis occurs either in concert with mitochondria and is controlled by
Bcl-2 (Hacki et al., 2000), or occurs by a mechanism
independent of the mitochondrial pathway (Nakagawa et al., 2000). Interestingly, our results show that
Al administration leads to a decrease in the Bcl-2
levels also in the endoplasmic reticulum, and that
these Bcl-2 levels are restored by GDNF treatment.
Thus, it appears that the endoplasmic reticulum may
play an important role in the initiation or the exacerbation of apoptosis induced by Al, with the possibility
that a key event is an increase in Bcl-2 in this organelle,
coupled with a concomitant increase in Bcl-X L, which

could sequester Apaf-1 and thereby contribute to the
antiapoptotic effect of GDNF. Such findings have been
reported, suggesting that Bcl-2 targeted to the endoplasmic reticulum is capable of blocking certain types
of apoptosis (Lee et al., 1999; Zhu et al., 1996). However, it remains unclear how Bcl-2 in the endoplasmic
reticulum exerts such an antiapoptotic effect. More
recently it has been demonstrated that stress in the
endoplasmic reticulum activates a specific apoptosis
pathway mediated by caspase-12 that is independent
from the mitochondrial apoptosis pathway (Nakagawa et al., 2000). Investigation of this caspase-12mediated endoplasmic reticulum apoptosis in our Almodel of neurodegeneration is important, and studies
are underway in our laboratory.
The activity most often attributed to GDNF is that of
promoting neuronal survival. GDNF binds to the
GDNF family receptor ␣ (GFR␣), with a higher affinity
to GFR␣1 than to GFR␣2 (Klein et al., 1997; Sanicola et
al., 1997) to form a complex that subsequently actiCopyright © 2001 by Academic Press
All rights of reproduction in any form reserved.
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vates the receptor tyrosine kinase, c-ret (Jing et al.,
1996). Upregulation of GDNF mRNA in rat brains has
been shown to occur following excitotoxicity induced
by glutamate (Ho et al., 1995) or kainate (Humpel et al.,
1994). GDNF has been shown to protect neurons
against oxidative stress in cultured mesencephalic
neurons and glial cells (Iwata-Ichikawa et al., 1999),
against ischemic/hypoxic-induced brain injury in
neonatal rats (Ikeda et al., 2000), after brain injury
following permanent middle cerebral artery occlusion
in rats (Kitagawa et al., 1998), and in primate models of
Parkinson’s disease (Kordower et al., 2000). The mechanisms by which GDNF exerts its neuroprotective effect are diverse, and recent evidence demonstrates
that the rescue and repair of injured neurons is a
consequence of an antiapoptotic action of GDNF. Indeed, GDNF has been shown to up-regulate Bcl-2 and
Bcl-X L levels in rat mesencephalic neurons subjected
to apoptosis, resulting in a reduction of caspase activation (Kitagawa et al., 1998; Sawada et al., 2000). The
present investigation not only confirms these antiapoptotic properties of GDNF, but further elucidates
the cell organelles in which the apoptosis-regulatory
proteins are controlled.
Apoptosis in neurodegenerative disorders, including Alzheimer’s disease, may be responsible for the
neuronal losses associated with these diseases. Therefore, the elucidation of the mechanisms of cell death
could culminate in the development of novel therapeutic strategies for prevention and therapy. We conclude that the intracisternal administration of the neurotoxin, Al maltolate, induces changes in the level of
proteins regulating apoptosis, and that GDNF regulates the increases in Bcl-2 and Bcl-X L, both of which
are antiapoptotic. This regulation, coupled with decreases in the proapoptotic Bax, serves to inhibit
apoptosis. Most importantly, these changes dramatically protect against the development of the acute,
severe, and invariably fatal neurological symptoms
associated with Al administration. Further experiments are needed to examine the long-term effects of
GDNF treatment on Al-induced fatal neurological
symptoms. We have performed a preliminary experiment with nine animals treated with Al maltolate and
GDNF and allowed to survive longer than the 3 days
reported in the present study. Five of these rabbits
developed neurological symptoms after 8 –9 days, and
the remaining four rabbits were asymptomatic up to 2
months. Because experimentally induced neurofibrillary degeneration resulting from Al administration
shares many features of the neurofibrillary pathology
in a number of human neurodegenerative disorders,
Copyright © 2001 by Academic Press
All rights of reproduction in any form reserved.

Ghribi et al.

particularly in Alzheimer’s disease, our results support proposed treatments with GDNF or related compounds as approaches to provide protection against
the neuronal loss associated with these conditions.
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